后抗生素时代的感染歼灭战 分享到
Fighting Infections in Post-antibiotic World 2018-06-1446172

中英
Việt-Anh
ไทย-อังกฤษ
英文

双击原文单词查看解释

原文跟读

Every year about 700000 people around the world die from infections caused by antibiotic resistant bacteria and that number keeps rising.Experts say if we do not find effective new drugs by 2050 the number of deaths could reach 10 million.One course of action is to develop viruses called phages that attack a specific strain of bacteria.For instance, Staphylococcus aureus that causes a range of hard to treat infections, crucial for this method is an enzyme called glycine.
全球每年约有70万人死于抗生素耐药性细菌引起的感染,这个数字还在不断上升。专家说,如果到2050年我们找不到有效的新药,死亡人数可能会达到1000万。一种方法是开发一种叫做噬菌体的病毒,这种病毒会攻击特定的细菌。例如,金黄色葡萄球菌运用这种方式就是一种叫做甘氨酸的酶,它能导致一系列难以治疗的感染。
“When you take that purified enzyme and add it back to a bacteria, for example, in an infection, it will drill a hole in the cell wall,the membrane externalizes like would normally do explode and kill the organism instantly.”
当你把纯化后的酶重新添加到细菌中,比如在感染中,它会在细胞壁上钻一个洞,细胞膜外化,就像爆炸一样立刻杀死生物体。
After 20 years of research, Fischetti managed to extract lysin from a bacteria eating phage.So the normally harmless virus itself is not used in the treatment, eliminating the danger it could mutate into a harmful form.“This is just a different way of killing bacteria, people are not comfortable with it yet.But I think once the first lysin gets through phase 2 clinical trials to show that it actually works and works well people will be more comfortable with it.And I think we’ll start using lysin in addition to antibiotics.”
经过20年的研究,菲谢蒂成功地从一个吃细菌的噬菌体中提取了溶菌素。因此,正常无害的病毒本身不被用于治疗,消除了它可能变异成有害形式的危险。这只是杀灭细菌的另一种方法,人们对它还不太习惯。但我认为一旦第一批溶菌素通过第二期临床试验,证明它确实有效且效果良好,人们会更容易接受它。我认为除了抗生素,我们还将开始使用溶菌素。
Biotechnology company contract successfully completed phase 1 of clinical tests,with a lysin called CF301 on healthy volunteers infected with Staphy aureus, the phase 2 trial is on their way.“We’re very encouraged by what we’ve seen, because it tells us that we can use the lysin in addition to conventional small-molecule antibiotics,completely different mechanism of action, without any observable adverse events.”In the meantime, researchers are trying to develop a lysin that will have the same effect on a different strain of antibiotic resistant bacteria that causes hospital acquired pneumonia.
生物技术公司成功完成了临床试验的第一阶段,在感染金黄色葡萄球菌的健康志愿者身上试用了被称为CF301的溶菌素,第二阶段试验正在进行中。我们对所见所闻感到非常鼓舞,因为它告诉我们除了传统的小分子抗生素外,我们还可以使用溶菌素,完全不同的作用机制,而不会出现任何明显的不良事件。与此同时,研究人员正在努力开发一种溶菌酶用来治疗获得性肺炎,因为现有病菌已经对现有抗生素产生了耐药性。
George Putic VOA News.
VOA记者乔治采访报道。

点击加载更多

我的生词本